1	V (CDN 146707)		
1	Lawrence H. Stone (SBN 146797) Lindsay L. Ryan (SBN 258130)		
2	David Z. Feingold (SBN 280194) 725 S. Figueroa Street, Suite 2500		
3	Los Angeles, CA 90017 Telephone: (213) 689-0404		
4	Facsimile: (213) 689-0430		
5	stonel@jacksonlewis.com lindsay.ryan@jacksonlewis.com		
6	david.feingold@jacksonlewis.com		
7	Attorneys for Defendant and Cross-Compla URIGEN PHARMACEUTICALS, INC.	inant	
8	AnnaMary E. Gannon (SBN 92175)		
9	amg@dillinghammurphy.com Barbara L. Harris Chiang (SBN 206832)		
10	bhc@dillinghammurphy.com DILLINGHAM & MURPHY LLP		
11	601California St., Suite 1900 San Francisco, CA 94108		
12	Telephone: (415) 397-2700 Facsimile: (415) 397-3300		
13	Attorneys for Plaintiff MARTIN E. SHMAGIN		
14	WAKTIN E. STIWAGIN		
15	UNITED STATES DISTRICT COURT		
16	NORTHERN DISTRICT OF CALIFORNIA		
17			
18	MARTIN E. SHMAGIN	CASE NO.: 12-c	
19	Plaintiff,	Hon. Jacqueline S	•
20	V.	JOINT CASE M CONFERENCE	
21	URIGEN PHARMACEUTICALS, INC.	Date:	August 29, 2013
22	Defendants.	Time: Courtroom:	1:30 p.m. "F"
23		Complaint Filed: FAC Filed:	May 22, 2012
<ul><li>24</li><li>25</li></ul>		FAC Filed: FAC Served: Trial Date:	May 22, 2012 June 1, 2012 June 15, 2012 October 7, 2013
26			
27			
28	GAGE NO. 12.2620 IGG	IOINI	T C A CE MANIA CEMI

CASE NO.: 12 2630 JSC

JOINT CASE MANAGEMENT CONFERENCE STATEMENT

## Case 3:12-cv-02630-JSC Document 57 Filed 08/29/13 Page 2 of 3

1	URIGEN PHARMACEUTICALS, INC.,	
2	Cross-Complainant,	
3	V.	
4	MARTIN E. SHMAGIN, an Individual;	
5	MARTIN E. SHMAGIN, an Individual; and DOES 1 through 10, inclusive, Cross-Defendants.	
6		
7		
8		
9		
10		
11		
12		
13		
14		
15		
16		
17 18		
19		
20		
21		
22		
23		
24		
25		
26		
27		
28		
	CASE NO.: 12 2630 JSC	JOINT CASE MANAGEMENT CONFERENCE STATEMENT

1	Defendant and Cross-Complainant URIGEN PHARMACEUTICALS, INC.			
2	("Defendant" or "Cross-Complainant" or "Urigen") and Plaintiff MARTIN E.			
3	SHMAGIN ("Plaintiff"), by and through their respective counsel of record, hereby			
4	submit the following update in advance of the scheduled Case Management Conference.			
5	After extensive negotiations and diligent efforts to finalize the complex settlement			
6	agreement reached in this matter, there remain only two provisions for which the parties			
7	are working to finalize the language. The parties anticipate resolving these issues shortly,			
8	and thereafter executing the Settlement Agreement, however, the agreement will not			
9	likely be executed in time to file a Request for Dismissal in advance of tomorrow's			
10	hearing. Accordingly, the parties would jointly request that the Court briefly continue the			
11	scheduled Case Management Conference by fourteen (14) days to <b>September 10, 2013</b> .			
12	Date: August 28, 2013 JACKSON LEWIS, LLP			
13				
14	By: /s/ Lawrence H. Stone Lawrence H. Stone			
15	Lindsay L. Ryan David Z. Feingold			
16	Attorneys for Defendant and Cross-			
17	Complainant URIGEN PHARMACEUTICALS, INC.			
18	ORIGEN FITARWACEO FICALS, INC.			
19	Date: August 28, 2013 Dillingham & Murphy, LLP			
20				
21	By: /s/ Barbara L. Harris Chiang			
22	AnnaMary E. Gannon Barbara L. Harris Chiang			
23	Attorneys for Plaintiff			
24	MARTÍN E. SHMAGIN			
25	The case management conference is continued to 9/12/13 at 1:30 p.m.			
26	Dated: 8/29/2013			
27	GRANTED SCORES			
28	a lacquelin's Scott Cortes (5)			
	CASE NO.: 12 2630 JSC  JOINT CASE MANAGEMENT CONFERENCE STATEMENT			